Investigation of novel alkyl/benzyl (4-sulphamoylphenyl)carbamimidothioates as carbonic anhydrase inhibitors

References

• a) Vermelho AB, Mori M, Donald WA, Supuran CT. Challenges and promises for obtaining new antiprotozoal drugs: What’s going wrong? In: Vermelho AB, Supuran CT, editors. Antiprotozoal drug development and delivery. Cham (Switzerland): Springer Nature; 2022. p. 321–330.
   Google Scholar
  b) Supuran CT, Capasso C. Carbonic anhydrases from pathogens: bacterial carbonic anhydrases and their inhibitors as potential antiinfectives. In: Supuran CT, Nocentini A, editors. Carbonic anhydrases – biochemistry and pharmacology of an evergreen pharmaceutical target. London (UK): Elsevier – Academic Press; 2019. p. 387–417.
   Google Scholar
  c) Capasso C, Supuran CT. Dihydropteroatesynthase (sulfonamides) and dihydrofolate reductase inhibitors. In: Bonev BB, Brown NM, editors. Bacterial resistance to antibiotics - from molecules to man. West Sussex (UK): John Wiley & Sons Ltd; 2020, p. 163–172.
   Google Scholar
• Wang S, Blahut M, Wu Y, Philipkosky KE, Outten FW. Communication between binding sites is required for YqjI regulation of target promoters within the yqjH-yqjI intergenic region. J Bacteriol. 2014;196(17):3199–3207.
   PubMed Web of Science ®Google Scholar
• a) Dupont CL, Butcher A, Valas RE, Bourne PE, Caetano-Anollés G. History of biological metal utilization inferred through phylogenomic analysis of protein structures. Proc Natl Acad Sci USA. 2010; 107 (23):10567–10572.
   PubMed Web of Science ®Google Scholar
  b) Supuran CT, Winum JY. Introduction to zinc enzymes as drug targets. In: Supuran CT, Winum JY, editors. Drug design of zinc-enzyme inhibitors: functional, structural, and disease applications. Hoboken (NJ): Wiley; 2009. p. 3–12.
   Google Scholar
• a) Supuran CT. Emerging role of carbonic anhydrase inhibitors. Clin Sci. 2021;135(10):1233–1249.
   PubMed Web of Science ®Google Scholar
  b) Supuran CT, Scozzafava A. Carbonic anhydrases as targets for medicinal chemistry. Bioorg Med Chem. 2007;15(13):4336–4350.
   PubMed Web of Science ®Google Scholar
  c) Supuran CT. Carbonic anhydrase inhibitors and their potential in a range of therapeutic areas. Expert Opin Ther Pat. 2018;28(10):709–712.
   PubMed Web of Science ®Google Scholar
  d) Supuran CT. Novel carbonic anhydrase inhibitors. Future Med Chem. 2021;13(22):1935–1937.
   PubMed Web of Science ®Google Scholar
• a) Alterio V, Di Fiore A, D'Ambrosio K, Supuran CT, De Simone G. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? Chem Rev. 2012;112(8):4421–4468.
   PubMed Web of Science ®Google Scholar
  b) Supuran CT. Anti-obesity carbonic anhydrase inhibitors: challenges and opportunities. J Enzyme Inhib Med Chem. 2022;37(1):2478–2488.
   PubMed Web of Science ®Google Scholar
  c) McDonald PC, Chafe SC, Supuran CT, Dedhar S. Cancer therapeutic targeting of hypoxia induced carbonic anhydrase IX: from bench to bedside. Cancers. 2022;14(14):3297.
   PubMed Web of Science ®Google Scholar
  d) Supuran CT. Multitargeting approaches involving carbonic anhydrase inhibitors: hybrid drugs against a variety of disorders. J Enzyme Inhib Med Chem. 2021;36(1):1702–1714.
   PubMed Web of Science ®Google Scholar
• a) Saad AE, Ashour DS, Rayia DMA, Bedeer AE. Carbonic anhydrase enzyme as a potential therapeutic target for experimental trichinellosis. Parasitol Res. 2016;115(6):2331–2339.
   PubMed Web of Science ®Google Scholar
  b) Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov. 2008;7(2):168–181.
   PubMed Web of Science ®Google Scholar
  c) Supuran CT. Carbonic anhydrase inhibition and the management of neuropathic pain. Expert Rev Neurother. 2016;16(8):961–968.
   PubMed Web of Science ®Google Scholar
  d) Carta F, Scozzafava A, Supuran CT. Sulfonamides: a patent review (2008–2012). Expert Opin Ther Pat. 2012;22(7):747–758.
   PubMed Web of Science ®Google Scholar
  e) Mishra CB, Tiwari M, Supuran CT. Progress in the development of human carbonic anhydrase inhibitors and their pharmacological applications: where are we today? Med Res Rev. 2020;40(6):2485–2565.
   PubMed Web of Science ®Google Scholar
• a) Nocentini A, Angeli A, Carta F, Winum JY, Žalubovskis R, Carradori S, Capasso C, Donald WA, Supuran CT. Reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase. J Enzyme Inhib Med Chem. 2021;36(1):561–580.
   PubMed Web of Science ®Google Scholar
  b) Abdoli M, Bonardi A, Supuran CT, Žalubovskis R. 4-Cyanamidobenzenesulfonamide derivatives: a novel class of human and bacterial carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem. 2023;38(1):156–165.
   PubMed Web of Science ®Google Scholar
  c) Supuran CT. Carbonic anhydrase inhibitors: an update on experimental agents for the treatment and imaging of hypoxic tumors. Expert Opin Investig Drugs. 2021;30(12):1197–1208.
   PubMed Web of Science ®Google Scholar
  d) Supuran CT. Experimental carbonic anhydrase inhibitors for the treatment of hypoxic tumors. J Exp Pharmacol. 2020;12:603–617.
   PubMedGoogle Scholar
• a) Angeli A, Velluzzi A, Selleri S, Capasso C, Spadini C, Iannarelli M, Cabassi CS, Carta F, Supuran CT. Seleno containing compounds as potent and selective antifungal agents. ACS Infect Dis. 2022;8(9):1905–1919.
   PubMed Web of Science ®Google Scholar
  b) D'Agostino I, Mathew GE, Angelini P, Venanzoni R, Angeles Flores G, Angeli A, Carradori S, Marinacci B, Menghini L, Abdelgawad MA, et al. Biological investigation of N-methyl thiosemicarbazones as antimicrobial agents and bacterial carbonic anhydrases inhibitors. J Enzyme Inhib Med Chem. 2022;37(1):986–993.
   PubMed Web of Science ®Google Scholar
  c) De Luca V, Angeli A, Mazzone V, Adelfio C, Carginale V, Scaloni A, Carta F, Selleri S, Supuran CT, Capasso C, et al. Heterologous expression and biochemical characterisation of the recombinant β-carbonic anhydrase (MpaCA) from the warm-blooded vertebrate pathogen malassezia pachydermatis. J Enzyme Inhib Med Chem. 2022;37(1):62–68.
   PubMed Web of Science ®Google Scholar
  d) De Luca V, Angeli A, Mazzone V, Adelfio C, Carta F, Selleri S, Carginale V, Scaloni A, Supuran CT, Capasso C, et al. Inhibitory effects of sulfonamide derivatives on the β-carbonic anhydrase (MpaCA) from Malassezia pachydermatis, a commensal, pathogenic fungus present in domestic animals. IJMS. 2021;22(22):12601.
   Google Scholar
  e) Supuran CT, Capasso C. A highlight on the inhibition of fungal carbonic anhydrases as drug targets for the antifungal armamentarium. IJMS. 2021;22(9):4324.
   Google Scholar
• a) Zimmerman SA, Ferry JG, Supuran CT. Inhibition of the archaeal beta-class (Cab) and gamma-class (Cam) carbonic anhydrases. Curr Top Med Chem. 2007;7(9):901–908.
   PubMed Web of Science ®Google Scholar
  b) Supuran CT, Clare BW. Carbonic anhydrase inhibitors. Part 57. Quantum chemical QSAR of a group of 1,3,4-thiadiazole and 1,3,4-thiadiazoline disulfonamides with carbonic anhydrase inhibitory properties. Eur J Med Chem. 1999;34(1):41–50.
   Web of Science ®Google Scholar
  c) Supuran CT, Barboiu M, Luca C, Pop E, Brewster ME, Dinculescu A. Carbonic anhydrase activators. Part 14. Synthesis of mono- and bis- pyridinium salt derivatives of 2-amino-5-(2-aminoethyl)- and 2-amino-5-(3-aminopropyl)-1,3,4-thiadiazole, and their interaction with isozyme II. Eur J Med Chem. 1996;31(7-8):597–606.
   Web of Science ®Google Scholar
  d) Aspatwar A, Barker H, Aisala H, Zueva K, Kuuslahti M, Tolvanen M, Primmer CR, Lumme J, Bonardi A, Tripathi A, et al. Cloning, purification, kinetic and anion inhibition studies of a recombinant β-carbonic anhydrase from the Atlantic salmon parasite platyhelminth Gyrodactylussalaris. J Enzyme Inhib Med Chem. 2022;37(1):1577–1586.
   PubMed Web of Science ®Google Scholar
• Scott KA, Njardarson JT. Analysis of US FDA-approved drugs containing sulfur atoms. Top Curr Chem. 2018;376(1):5.
   PubMed Web of Science ®Google Scholar
• a) Abdoli M, Giovannuzzi S, Supuran CT, Žalubovskis R. 4-(3-Alkyl/benzyl-guanidino)benzenesulfonamides as selective carbonic anhydrase VII inhibitors. J Enzyme Inhib Med Chem. 2022;37(1):1568–1576.
   PubMed Web of Science ®Google Scholar
  b) Abdoli M, Angeli A, Bozdag M, Carta F, Kakanejadifard A, Saeidian H, Supuran CT. Synthesis and carbonic anhydrase I, II, VII, and IX inhibition studies with a series of benzo [d] thiazole-5-and 6-sulfonamides. J Enzyme Inhib Med Chem. 2017;32(1):1071–1078.
   PubMed Web of Science ®Google Scholar
  c) Abdoli M, Bozdag M, Angeli A, Supuran CT. Benzamide-4-sulfonamides are effective human carbonic anhydrase i, ii, vii, and ix inhibitors. Metabolites. 2018;8(2):37.
   PubMed Web of Science ®Google Scholar
• a) Petreni A, Iacobescu A, Simionescu N, Petrovici AR, Angeli A, Fifere A, Pinteala M, Supuran CT. Carbonic anhydrase inhibitors bearing organotelluride moieties as novel agents for antitumor therapy. Eur J Med Chem. 2022;244:114811.
   PubMed Web of Science ®Google Scholar
  b) Artasensi A, Angeli A, Lammi C, Bollati C, Gervasoni S, Baron G, Matucci R, Supuran CT, Vistoli G, Fumagalli L. Discovery of a potent and highly selective dipeptidyl peptidase IV and carbonic anhydrase inhibitor as "antidiabesity" agents based on repurposing and morphing of WB-4101. J Med Chem. 2022;65(20):13946–13966.
   PubMed Web of Science ®Google Scholar
  c) Najm MAA, Mahmoud WR, Taher AT, Abbas SE, Awadallah FM, Allam HA, Vullo D, Supuran CT. Design and synthesis of some new benzoylthioureido phenyl derivatives targeting carbonic anhydrase enzymes. J Enzyme Inhib Med Chem. 2022;37(1):2702–2709.
   PubMedGoogle Scholar
• a) Al-Warhi T, Elbadawi MM, Bonardi A, Nocentini A, Al-Karmalawy AA, Aljaeed N, Alotaibi OJ, Abdel-Aziz HA, Supuran CT, Eldehna WM. Design and synthesis of benzothiazole-based SLC-0111 analogues as new inhibitors for the cancer-associated carbonic anhydrase isoforms IX and XII. J Enzyme Inhib Med Chem. 2022;37(1):2635–2643.
   PubMed Web of Science ®Google Scholar
  b) Biagiotti G, Angeli A, Giacomini A, Toniolo G, Landini L, Salerno G, Di Cesare Mannelli L, Ghelardini C, Mello T, Mussi S, et al. Glyco-coated CdSe/ZnS quantum dots as nanoprobes for carbonic anhydrase IX imaging in cancer cells. ACS Appl Nano Mater. 2021;4(12):14153–14160.
   PubMed Web of Science ®Google Scholar
  c) Vannozzi G, Vullo D, Angeli A, Ferraroni M, Combs J, Lomelino C, Andring J, Mckenna R, Bartolucci G, Pallecchi M, et al. One-pot procedure for the synthesis of asymmetric substituted ureido benzene sulfonamides as effective inhibitors of carbonic anhydrase enzymes. J Med Chem. 2022;65(1):824–837.
   PubMed Web of Science ®Google Scholar
• a) Urbanski LJ, Vullo D, Parkkila S, Supuran CT. An anion and small molecule inhibition study of the β-carbonic anhydrase from Staphylococcus aureus. J Enzyme Inhib Med Chem. 2021;36(1):1088–1092.
   PubMed Web of Science ®Google Scholar
  b) Urbanski LJ, Bua S, Angeli A, Kuuslahti M, Hytönen VP, Supuran CT, Parkkila S. Sulphonamide inhibition profile of Staphylococcus aureus β-carbonic anhydrase. J Enzyme Inhib Med Chem. 2020;35(1):1834–1839.
   PubMed Web of Science ®Google Scholar
• a) Nishimori I, Minakuchi T, Vullo D, Scozzafava A, Supuran CT. Inhibition studies of the β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium with sulfonamides and sulfamates. Bioorg Med Chem. 2011;19(16):5023–5030.
   PubMed Web of Science ®Google Scholar
  b) Vullo D, Nishimori I, Minakuchi T, Scozzafava A, Supuran CT. Inhibition studies with anions and small molecules of two novel β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium. Bioorg Med Chem Lett. 2011;21(12):3591–3595.
   PubMed Web of Science ®Google Scholar
  c) Supuran CT. Bacterial carbonic anhydrases as drug targets: toward novel antibiotics? Front Pharmacol. 2011;2:34.
   PubMed Web of Science ®Google Scholar
• Angeli A, Urbański LJ, Capasso C, Parkkila S, Supuran CT. Activation studies with amino acids and amines of a β-carbonic anhydrase from Mammaliicoccus (Staphylococcus) sciuri previously annotated as Staphylococcus aureus (SauBCA) carbonic anhydrase. J Enzyme Inhib Med Chem. 2022;37(1):2786–2792.
   PubMed Web of Science ®Google Scholar
• a) De Simone G, Di Fiore A, Truppo E, Langella E, Vullo D, Supuran CT, Monti SM. Exploration of the residues modulating the catalytic features of human carbonic anhydrase XIII by a site-specific mutagenesis approach. J Enzyme Inhib Med Chem. 2019;34(1):1506–1510.
   PubMed Web of Science ®Google Scholar
  b) Monti DM, De Simone G, Langella E, Supuran CT, Di Fiore A, Monti SM. Insights into the role of reactive sulfhydryl groups of carbonic anhydrase III and VII during oxidative damage. J Enzyme Inhib Med Chem. 2017;32(1):5–12.
   PubMed Web of Science ®Google Scholar
• a) Payaz DÜ, Küçükbay FZ, Küçükbay H, Angeli A, Supuran CT. Synthesis carbonic anhydrase enzyme inhibition and antioxidant activity of novel benzothiazole derivatives incorporating glycine, methionine, alanine, and phenylalanine moieties. J Enzyme Inhib Med Chem. 2019;34(1):343–349.
   PubMed Web of Science ®Google Scholar
  b) José O, Torres-Rodríguez P, Forero-Quintero LS, Chávez JC, De la Vega-Beltrán JL, Carta F, Supuran CT, Deitmer JW, Treviño CL. Carbonic anhydrases and their functional differences in human and mouse sperm physiology. Biochem Biophys Res Commun. 2015;468(4):713–718.
   PubMed Web of Science ®Google Scholar
  c) Bootorabi F, Jänis J, Hytönen VP, Valjakka J, Kuuslahti M, Vullo D, Niemelä O, Supuran CT, Parkkila S. Acetaldehyde-derived modifications on cytosolic human carbonic anhydrases. J Enzyme Inhib Med Chem. 2011;26(6):862–870.
   PubMed Web of Science ®Google Scholar
• Khalifah RG. The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C. J Biol Chem. 1971;246(8):2561–2573.
   PubMed Web of Science ®Google Scholar
• a)Pastorekova S, Casini A, Scozzafava A, Vullo D, Pastorek J, Supuran CT. Carbonic anhydrase inhibitors: the first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX. Bioorg Med Chem Lett. 2004;14(4):869–873.
   PubMed Web of Science ®Google Scholar
  b) Vullo D, Voipio J, Innocenti A, Rivera C, Ranki H, Scozzafava A, Kaila K, Supuran CT. Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides. Bioorg Med Chem Lett. 2005;15(4):971–976.
   PubMed Web of Science ®Google Scholar
  c) Gieling RG, Babur M, Mamnani L, Burrows N, Telfer BA, Carta F, Winum J-Y, Scozzafava A, Supuran CT, Williams KJ, et al. Antimetastatic effect of sulfamate carbonic anhydrase IX inhibitors in breast carcinoma xenografts. J Med Chem. 2012;55(11):5591–5600.
   PubMed Web of Science ®Google Scholar
  d) Grandane A, Nocentini A, Werner T, Zalubovskis R, Supuran CT. Benzoxepinones: a new isoform-selective class of tumor associated carbonic anhydrase inhibitors. Bioorg Med Chem. 2020;28(11):115496.
   PubMed Web of Science ®Google Scholar
• a) Krasavin M, Sharonova T, Sharoyko V, Zhukovsky D, Kalinin S, Žalubovskis R, Tennikova T, Supuran CT. Combining carbonic anhydrase and thioredoxin reductase inhibitory motifs within a single molecule dramatically increases its cytotoxicity. J Enzyme Inhib Med Chem. 2020;35(1):665–671.
   PubMed Web of Science ®Google Scholar
  b) Ivanova J, Balode A, Žalubovskis R, Leitans J, Kazaks A, Vullo D, Tars K, Supuran CT. 5-Substituted-benzylsulfanyl-thiophene-2-sulfonamides with effective carbonic anhydrase inhibitory activity: Solution and crystallographic investigations. Bioorg Med Chem. 2017;25(3):857–863.
   PubMed Web of Science ®Google Scholar
  c) Alterio V, Tanc M, Ivanova J, Zalubovskis R, Vozny I, Monti SM, Di Fiore A, De Simone G, Supuran CT. X-ray crystallographic and kinetic investigations of 6-sulfamoyl-saccharin as a carbonic anhydrase inhibitor. Org Biomol Chem. 2015; 13(13):4064–4069.
   PubMed Web of Science ®Google Scholar
• a) Luchinat E, Barbieri L, Cremonini M, Pennestri M, Nocentini A, Supuran CT, Banci L. Determination of intracellular protein-ligand binding affinity by competition binding in-cell NMR. Acta Crystallogr D Struct Biol. 2021;77(Pt 10):1270–1281.
   PubMedGoogle Scholar
  b) Berrino E, Michelet B, Martin-Mingot A, Carta F, Supuran CT, Thibaudeau S. Modulating the efficacy of carbonic anhydrase inhibitors through fluorine substitution. Angew Chem Int Ed Engl. 2021;60(43):23068–23082.
   PubMed Web of Science ®Google Scholar
• a) Bouzina A, Berredjem M, Nocentini A, Bua S, Bouaziz Z, Jose J, Le Borgne M, Marminon C, Gratteri P, Supuran CT. Ninhydrins inhibit carbonic anhydrases directly binding to the metal ion. Eur J Med Chem. 2021;209:112875.
   PubMed Web of Science ®Google Scholar
  b) Angeli A, Carta F, Nocentini A, Winum JY, Zalubovskis R, Akdemir A, Onnis V, Eldehna WM, Capasso C, Simone G, et al. Carbonic Anhydrase Inhibitors Targeting Metabolism and Tumor Microenvironment. Metabolites. 2020;10(10):412.
   PubMed Web of Science ®Google Scholar